EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report

Ilva Kristiana Langrate, Elisabeth Kretschmer-Chott, Stefan Schmitl, Shahrokh F Shariat, Marcus Hacker, Gero Kramer, Sazan Rasul

Wiener klinische Wochenschrift · 2025

DOI: 10.1007/s00508-025-02642-3 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Ilva Kristiana Langrate und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antigens, Surface, Bone Neoplasms, Glutamate Carboxypeptidase II, Lutetium. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The [ 177 Lu]Lu-PSMA radioligand therapy is a prostate-specific membrane antigen (PSMA) targeting treatment approved for patients with metastatic castration-resistant prostate cancer, after failure of androgen deprivation therapy or taxane-based chemotherapy. We report a unique case of a patient with metastatic hormone-sensitive prostate cancer (mHSPC) who received PSMA radioligand therapy as the sole treatment, without any prior or additional systemic treatment. Over a span of 8 years, the patient underwent 12 cycles of [ 177 Lu]Lu-PSMA radioligand therapy, demonstrating favorable therapeutic response and a prolonged androgen deprivation therapy-free period. This case highlights the potential of long-term PSMA radioligand therapy as a standalone option in selected mHSPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceBone NeoplasmsGlutamate Carboxypeptidase IILutetiumProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsHumansMaleDipeptidesProstate-Specific Antigen

Stichwörter der Autor:innen

Androgen deprivation therapyPSAPSMA radioligand therapyTheranosticsmHSPC

Substanzen

Antigens, SurfaceDipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumlutetium (177Lu) vipivotide tetraxetanLutetium-177Prostate-Specific AntigenRadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA.
  • Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan.
  • Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Department of Urology, Weill Cornell Medical College, New York, USA.

Förderung

  • Medical University of Vienna

Zitieren

APA

Langrate, I. K., Kretschmer-Chott, E., Schmitl, S., Shariat, S. F., Hacker, M., Kramer, G., & Rasul, S. (2025). [177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-025-02642-3

Vancouver

Langrate IK, Kretschmer-Chott E, Schmitl S, Shariat SF, Hacker M, Kramer G, et al. [177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-025-02642-3

BibTeX
@article{Langrate2025,
  author = {Langrate, Ilva Kristiana and Kretschmer-Chott, Elisabeth and Schmitl, Stefan and Shariat, Shahrokh F and Hacker, Marcus and Kramer, Gero and Rasul, Sazan},
  title = {[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report},
  journal = {Wiener klinische Wochenschrift},
  year = {2025},
  doi = {10.1007/s00508-025-02642-3}
}
Kostenlos starten →